Friday, March 17, 2017

Moximed Gets $50M

Hayward-based Moximed, a developer of implants used to treat patients with knee osteoarthritis (OA), has raised $50M in a Series F funding, the company said this week. The funding came from Advent Life Sciences and Future Fund, along with NEA, Morgenthaler Ventures, Gilde Healthcare, GBS Venture Partners, and Vertex Healthcare. Shahzad Malik of Advent and Brigitte Smith of GBS join the company's board. Moximed develops shock absorbing implants for treating patients with knee OA.